高级检索
    闫小龙, 夏津. 厄洛替尼对比长春瑞滨联合顺铂辅助治疗ⅢA期EGFR突变阳性非小细胞肺癌患者的疗效[J]. 循证医学, 2019, 19(1): 44-46. DOI: 10.12019/j.issn.1671-5144.2019.01.012
    引用本文: 闫小龙, 夏津. 厄洛替尼对比长春瑞滨联合顺铂辅助治疗ⅢA期EGFR突变阳性非小细胞肺癌患者的疗效[J]. 循证医学, 2019, 19(1): 44-46. DOI: 10.12019/j.issn.1671-5144.2019.01.012
    shu
    YAN Xiao-long, XIA Jin. Efficacy of Erlotinib Versus Vinorelbine Plus Cisplatin as Adjuvant Therapy for StageⅢA EGFR Mutation-Positive Non-Small Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2019, 19(1): 44-46. DOI: 10.12019/j.issn.1671-5144.2019.01.012
    Citation: YAN Xiao-long, XIA Jin. Efficacy of Erlotinib Versus Vinorelbine Plus Cisplatin as Adjuvant Therapy for StageⅢA EGFR Mutation-Positive Non-Small Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2019, 19(1): 44-46. DOI: 10.12019/j.issn.1671-5144.2019.01.012
    shu

    厄洛替尼对比长春瑞滨联合顺铂辅助治疗ⅢA期EGFR突变阳性非小细胞肺癌患者的疗效

    Efficacy of Erlotinib Versus Vinorelbine Plus Cisplatin as Adjuvant Therapy for StageⅢA EGFR Mutation-Positive Non-Small Cell Lung Cancer

      摘要
      • HTML全文
      • 参考文献(0)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回